Van K Morris
SWOG Cancer Research Network · NRG Oncology · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Van K Morris as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05308446 · Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationNational Cancer Institute (NCI) · active not recruiting · Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8 · principal investigator
- Ph2/Ph3NCT04068103 · Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After SurgeryNRG Oncology · active not recruiting · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT04017650 · Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerM.D. Anderson Cancer Center · active not recruiting · BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma · principal investigator
- Ph1/Ph2NCT03436563 · M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityM.D. Anderson Cancer Center · completed · Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Multi-omic liquid biopsy assessment in NCI trials: evaluating ctDNA, extravesicle RNA, and outcomes with immunotherapy in patient with colorectal and anal cancersR50CA285403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $181,640 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT05308446
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT04068103
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:06 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.Lancet Oncol · 2017320 citationsRCR 9.2
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).J Clin Oncol · 2021295 citationsRCR 15.5
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.Cancer Discov · 2016198 citationsRCR 5.4
- Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.N Engl J Med · 2025124 citationsRCR 28.3
- Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial.Lancet Gastroenterol Hepatol · 202561 citationsRCR 23.8
- A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.Oncologist · 202357 citationsRCR 4.9
- Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).J Immunother Cancer · 202247 citationsRCR 2.6
- Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.Oncologist · 202329 citationsRCR 2.8
- First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.J Immunother Cancer · 202427 citationsRCR 2.6
- Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer.Cancer Cell · 202524 citationsRCR 5.0